ClinicalTrials.gg
Not yet recruitingNCT07096115Updated Jul 31, 2025

ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly

An interventional study of Taiglididine in Urological Surgery, sponsored by The First People's Hospital of Lianyungang. Not yet recruiting. Open to participants aged 65 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by The First People's Hospital of Lianyungang · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
65 Years to 80 Years
Sex
All
01

Study summary

This research protocol aims to investigate the 90% effective dose (ED90) of taiglididine for inhibiting laryngeal mask insertion response in elderly patients. It is a non-randomized controlled trial using a biased coin design up-down method (BCD-UDM). A total of 54 elderly patients aged 65-80 years with ASA I-III, BMI 18-30 kg/m², and suitable for urological surgery under general anesthesia with laryngeal mask insertion will be enrolled. The first patient receives an intravenous injection of 1 mg taiglididine, followed by propofol and rocuronium. Subsequent doses of taiglididine are adjusted dynamically based on the previous patient's response: increasing by 0.1 mg if the insertion response is positive, or using BCD-UDM (11% probability to decrease by 0.1 mg, 89% to remain) if negative. The primary efficacy endpoint is the occurrence of laryngeal mask insertion response, while secondary endpoints include adverse events, vital sign changes, insertion success rate, and various time intervals. Safety is evaluated by monitoring vital signs. Statistical analysis will use SPSS 25.0 and R software to calculate ED90 and 95% confidence intervals via probit regression and bootstrap method, with at least 45 valid patients required to complete the trial.

02

Conditions studied

  • Urological Surgery

Keywords

  • Taiglididine
  • Elderly Patients
03

In context

Lead sponsor

The First People's Hospital of Lianyungang is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 65-80 years old.
  2. I-III.
  3. 18-30 kg/m² (inclusive of critical values).
  4. Mallampati class I or II, mouth opening >2.5 cm.
  5. No abnormal airway or head/neck conditions.
  6. No risk of reflux or aspiration (e.g., full stomach, obesity, gastrointestinal obstruction).
  7. Expected surgery duration \<180 min.
  8. Scheduled for urological surgery requiring general anesthesia and laryngeal mask insertion.
  9. Voluntary participation with signed .

Exclusion criteria

Exclusion Criteria:

Baseline measurements: Severe hypertension (SBP >160 mmHg or DBP >100 mmHg), heart rate \<60 bpm or >100 bpm.

2. History of long-term alcohol, sedative, or analgesic use; allergy to any study drugs.

3. Severe dysfunction of vital organs (heart, lung, liver, kidney, nervous system), neuromuscular diseases, hyperthyroidism, obstructive sleep apnea syndrome.

4. History of mental disorders or cognitive impairment severe enough to hinder understanding or cooperation with the study.

5. Preoperative administration of sedative-hypnotics (including benzodiazepines and barbiturates).

6. Upper respiratory tract infection within 1 month before surgery. 7. Participation in other clinical studies within the past 3 months. 8. Other conditions deemed unsuitable for the trial by the investigator.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Taiglididine Sequential Dose-Finding for LMA Insertion Suppression

    Drug: Taiglididine

Interventions

  • DrugTaiglididine

    The first patient receives an intravenous injection of 1 mg taiglididine for anesthesia induction, followed by 1-2 mg/kg propofol. When the patient's bispectral index (BIS) drops below 60, eyelash reflex disappears, and MOAA/S score is 0, intravenous rocuronium 0.6 mg/kg is given, and a laryngeal mask is inserted by a senior anesthesiologist using a unified method 1 min later. From the second patient onward, the taiglididine dose is dynamically adjusted based on the previous patient's response to laryngeal mask insertion using BCD-UDM: if the previous patient shows a positive insertion response (positive response or MOAA/S ≥2 within 2 min after induction), the next patient's dose increases by 0.1 mg; if negative, a random number (1-95) generated by computer determines the dose: doses remain unchanged when the number is 6-95 (89% probability) and decrease by 0.1 mg when the number is 1-5 (11% probability). A collaborator not involved in result evaluation provides a sealed envelope with

06

What researchers measure

Primary outcomes

  1. Number of patients with positive laryngeal mask insertion response

    If the patient has movement during laryngeal mask insertion, twitching at the corner of the mouth, coughing, frowning, tearing, laryngospasm, bispectral index not decreasing to below 60, an increase in heart rate or blood pressure of more than 20% of the baseline value within 2 minutes after laryngeal mask insertion, tachycardia (heart rate \>120 beats per minute), or hypertension (systolic blood pressure \>180 mmHg), and one of these occurs, it is determined as a positive laryngeal mask insertion reaction; otherwise, it is negative.

    Time frame: Perioperative

Secondary outcomes

  1. Number of adverse reactions

    Blood pressure elevation (systolic blood pressure/diastolic blood pressure \>20% baseline), hypotension (systolic blood pressure/diastolic blood pressure \<20% baseline or \<85/50 mmHg), bradycardia (heart rate \<50 bpm), tachycardia (heart rate \>100 bpm), hypoxemia (pulse oximetry \<92%), When 2 ml of propofol is injected, the patient is asked if there is any injection pain.

    Time frame: Perioperative

  2. Number of successful cases of laryngeal mask placement

    Number of successful cases of laryngeal mask placement

    Time frame: Perioperative

  3. Adverse reactions such as pain, dizziness, headache, nausea and vomiting, sore throat, chills, choking, agitation, hoarseness of voice, and Intraoperative knowledge

    The number of adverse reactions

    Time frame: Perioperative

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07096115
Lead sponsor
The First People's Hospital of Lianyungang
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 31, 2025

Study contacts

zhibin Zhao
Contact
lygzhaozhibin@163.com
+8618961326661

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion